Clinical and Antimicrobial Susceptibility Data of 140 Streptococcus pseudopneumoniae Isolates in France

Laurens, C.; Michon, Anne-Laure; Marchandin, Hélène; Bayette, J.; Didelot, Marie-Noëlle; Jean-Pierre, Hélène

doi:10.1128/aac.06374-11

Cited by 29 publications

(30 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Streptococcus mitis is a commensal organism typically found in the oropharynx and sometimes associated with invasive disease, particularly in immunocompromised individuals. Although S. pseudopneumoniae is occasionally isolated from respiratory and blood specimens, its clinical significance is not yet well defined (52)(53)(54)(55). The first strain of S. peroris to be described was isolated from the pharynx of a child (56), and so far, isolates from both healthy and unhealthy individuals appear to be extremely rare.…”

Section: Discussionmentioning

confidence: 99%

Development of an Extended-Specificity Multiplex Immunoassay for Detection of Streptococcus pneumoniae Serotype-Specific Antigen in Urine by Use of Human Monoclonal Antibodies

Eletu

Sheppard

Thomas

et al. 2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

Current pneumococcal vaccines cover the 10 to 23 most common serotypes of the 92 presently described. However, with the increased usage of pneumococcal-serotype-based vaccines, the risk of serotype replacement and an increase in disease caused by nonvaccine serotypes remains. Serotype surveillance of pneumococcal infections relies heavily on culture techniques, which are known to be insensitive, particularly in cases of noninvasive disease. Pneumococcal-serotypespecific urine assays offer an alternative method of serotyping for both invasive and noninvasive disease. However, the assays described previously cover mainly conjugate vaccine serotypes, give little information about circulating nonvaccine serotypes, and are currently available only in one or two specialist laboratories. Our laboratory has developed a Luminex-based extended-range antigen capture assay to detect pneumococcal-serotype-specific antigens in urine samples. The assay targets 24 distinct serotypes/serogroups plus the cell wall polysaccharide (CWP) and some cross-reactive serotypes. We report that the assay is capable of detecting all the targeted serotypes and the CWP at 0.1 ng/ml, while some serotypes are detected at concentrations as low as 0.3 pg/ml. The analytical serotype specificity was determined to be 98.4% using a panel of polysaccharide-negative urine specimens spiked with nonpneumococcal bacterial antigens. We also report clinical sensitivities of 96.2% and specificities of 89.9% established using a panel of urine specimens from patients diagnosed with community-acquired pneumonia or pneumococcal disease. This assay can be extended for testing other clinical samples and has the potential to greatly improve serotype-specific surveillance in the many cases of pneumococcal disease in which a culture is never obtained.KEYWORDS diagnostics, immunization, monoclonal antibodies, pneumococcus, surveillance studies D espite being vaccine preventable, Streptococcus pneumoniae (pneumococcus) remains a major cause of morbidity and mortality worldwide. Pneumococcal disease (PD) includes both invasive and noninvasive disease. The former includes bacteremia and meningitis; the latter, nonbacteremic pneumonia, sinusitis, and acute otitis media. To date, 97 "serotypes" of pneumococcus have been reported (1); however, some of these show only genotypic differences and produce the same polysaccharide structures (2). Ninety-two serotypes are currently described by the Danish system using commercial typing sera from SSI Diagnostica AG (Hillerød, Denmark). These serotypes differ in

show abstract

Section: Discussionmentioning

confidence: 99%

Development of an Extended-Specificity Multiplex Immunoassay for Detection of Streptococcus pneumoniae Serotype-Specific Antigen in Urine by Use of Human Monoclonal Antibodies

Eletu

Sheppard

Thomas

et al. 2017

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…COPD with infected exacerbation and previous hospitalization with COPD were significantly associated with increase in the acquisition of S. pseudopneumoniae in spite of large number of studied cases suffering from COPD in this research. The association of COPD with S. pseudopneumoniae infection has been documented by previous studies (Keith et al, 2006;Harf-Monteil et al, 2006), however other studies have recorded that S. pseudopneumoniae were more frequently associated with bronchitis and pneumonia rather than COPD (Laurens et al, 2012). To determine the actual role of S. pseudopneumoniae in COPD exacerbation, cohort studies for patients during periods of exacerbation and stability of COPD is recommended to observe the appearance of new S. pseudopneumoniae isolates in the exacerbation periods that could confirm the association of infection with new bacterial strains and COPD exacerbation (Sethi et al, 2002).…”

Section: Discussionmentioning

confidence: 77%

“…This observation was also supported by the presence of pulmonary infiltrate in 37.5% and elevated leukocyte count in 31.2% of cases with culture positive S. pseudopneumoniae. Although a high resistance rate of S. pseudopneumoniae to various classes of antibiotics has been documented in previous studies, most of them suspected this organism as a colonizing bacterium of the respiratory tract or a weak opportunistic pathogen that is usually associated with potentially pathogenic organisms in patients with chronic conditions (Laurens et al, 2012). Subsequent studies have supported our finding that this organism may have a real clinical importance depending on the observed high resistance rate for this organism together with its involvement in various types of invasive diseases (Rolo et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…pseudopneumoniae was firstly described in sputum samples of patients with lower respiratory tract infection, particularly those with Chronic Obstructive Pulmonary Diseases (COPD) (Laurens et al, 2012). The clinical relevance and pathogenic potential of this organism has not been clearly determined except in few studies that were conducted on mouse models with sepsis and peritonitis, so the correct identification and rapid detection of this emerging pathogen in clinical setting is very important for determination of its disease potential (HarfMonteil et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Streptococcus pseudopneumoniae as an emerging pathogen from patients with respiratory diseases

El-Kazzaz¹,

El-Khier²,

Arram³

2017

Afr. J. Microbiol. Res.

View full text Add to dashboard Cite

Streptococcus pseudopneumoniae is a mischaracterized species of Streptococci that is usually overlooked during examination of sputum samples of patients with chest infections. The association of this organism with lower respiratory tract diseases is still unclear and its isolation and description is underestimated in our locality. To our knowledge, there are no published studies on the isolation of S. pseudopneumoniae from pathological specimens in Egypt. The aims of this study were to isolate S. pseudopneumoniae from sputum specimens of patients admitted to Chest Department of Mansoura University Hospitals (MUHs) and to differentiate it from Streptococcus pneumoniae and other viridans group Streptococci, also to determine its prevalence and associated risk factors. Sixteen isolates of S. pseudopneumoniae were diagnosed phenotypically by optochin susceptibility and bile solubility tests followed by genotypic characterization by multiplex polymerase chain reaction (PCR). All of the isolates were subjected to antibiotic susceptibility testing using the disk diffusion method. The prevalence of S. pseudopneumoniae among studied patients was 4.9% (16/329). All of the examined isolates were found to be positive for aliB-like ORF2 and negative for cpsA and lytA genes by multiplex PCR. Elevated resistance rate of the isolates was recorded for erythromycin, penicillin and co-trimoxazole. Infection by S. pseudopneumoniae was found to be significantly associated with Chronic Obstructive Pulmonary Diseases (COPD). Although, S. pseudopneumoniae recorded a low prevalence in this study, their elevated antibiotic resistance together with the association with COPD and their pure isolation from sputum samples underline the necessity of spending more effort for their detection and characterization in the microbiology laboratories.

show abstract

“…pneumoniae in the respiratory tract is low (1% to 12%) (20)(21)(22), and it is more frequently present in sputum than in the nasopharynx (23). Moreover, our purpose here was not to evaluate this RT-PCR assay but to assess the lyophilization of DNA.…”

mentioning

confidence: 99%

Cost-Effective Pooling of DNA from Nasopharyngeal Swab Samples for Large-Scale Detection of Bacteria by Real-Time PCR

et al. 2015

View full text Add to dashboard Cite

We investigated the potential of pooling DNA from nasopharyngeal specimens to reduce the cost of real-time PCR (RT-PCR) for bacterial detection. Lyophilization is required to reconcentrate DNA. This strategy yields a high specificity (86%) and a high sensitivity (96%). We estimate that compared to individual testing, 37% fewer RT-PCR tests are needed. R eal-time PCR (RT-PCR) is an essential tool for routine diagnostics and large epidemiological studies of infectious diseases (1, 2). However, its cost remains significant and limits its use. To reduce it, samples can be pooled (3)(4)(5). This idea was suggested by Dorfman in 1943 (6) and has been used for the serological diagnosis of infectious diseases. Pooling samples is also an efficient way to screen for the nucleic acids of viruses, bacteria, or parasites (4,5,(7)(8)(9)(10)(11)(12)(13)(14)(15). However, pooling can decrease the sensitivity of assays due to the dilution of the samples, which is problematic in clinical diagnostics (16). Here, we investigated the potential of pooling DNA from clinical specimens using lyophilization to concentrate the pooled DNA and maintain the sensitivity of RT-PCR.We screened 2,380 nasopharyngeal swabs (Remel, USA) by RT-PCR to detect their rates of Streptococcus pneumoniae, Haemophilus influenzae, and Klebsiella pneumoniae carriage. DNA was extracted using a Macherey-Nagel NucleoSpin-96 kit. A total of 119 pools containing 80 l of DNA from 20 patients was frozen for 4 h at Ϫ20°C, lyophilized using a Lyovac GTZ instrument (Leybold Heraeus, France), and redissolved in 80 l of sterile water. The effectiveness of lyophilization was verified with pool controls, including one positive sample with a known threshold cycle (C T ) value for each bacterium. The specificities of the primers and probes (17, 18) were verified in silico by conducting a BLAST search in GenBank and performing RT-PCR on 10 to 15 closely related bacterial strains present in the respiratory tract (see Tables S1 and S2 in the supplemental material). RT-PCR was performed using 5 l of DNA per reaction and a 7900HT thermocycler (Applied Biosystems). Nuclease-free water was used as a negative control, and DNA from a clinical strain was used as a positive control. The cutoff C T value for positive results was Յ38. Each sample was also tested individually. The DNA extraction quality of each pool was verified by RT-PCR targeting the human beta-actin gene (19).The prevalences for the individual samples were 9% (215/ 2,380) for S. pneumoniae, 7% (169/2,380) for H. influenzae, and 4% (95/2,380) for K. pneumoniae. Among the pools tested, 69% (82/119) were positive for S. pneumoniae, 53% (63/119) were positive for H. influenzae, and 53% (63/119) were positive for K. pneumoniae (Table 1). Among them, 184/357 (52%) were truepositive results and 142/357 (40%) were true-negative results. However, 24/357 (7%) were false positives (negative individual samples), and 7/357 (2%) negative pools contained positive individual specimens, yielding false negatives (see Table S3 in the sup...

show abstract

Clinical and Antimicrobial Susceptibility Data of 140 Streptococcus pseudopneumoniae Isolates in France

Cited by 29 publications

References 10 publications

Development of an Extended-Specificity Multiplex Immunoassay for Detection of Streptococcus pneumoniae Serotype-Specific Antigen in Urine by Use of Human Monoclonal Antibodies

Development of an Extended-Specificity Multiplex Immunoassay for Detection of Streptococcus pneumoniae Serotype-Specific Antigen in Urine by Use of Human Monoclonal Antibodies

Streptococcus pseudopneumoniae as an emerging pathogen from patients with respiratory diseases

Cost-Effective Pooling of DNA from Nasopharyngeal Swab Samples for Large-Scale Detection of Bacteria by Real-Time PCR

Contact Info

Product

Resources

About